MacularorRetinalEdema near Union City, NJ

Biography: After graduating magna cum laude from Rensselaer Polytechnic Institute with a Bachelor of Science in biochemistry/biophysics, Dr. Haqqie graduated from Albany Medical College cum laude. She was inducted into the Alpha Omega Alphahonor society her junior year of medical college. She completed her residencyat Albany Medical College where she was selected to serve as chief resident in her final year and was awarded the Robert Reinecke research award. Dr. Haqqie then went on to complete her fellowship in cornea, cataract, and refractive surgery at Weill Cornell Medical College in New York, New York.Dr. Haqqie was previously the assistant director of the Wills Eye Hospital Emergency Department. During her time at Wills Eye Hospital, she was the recipient of the Residency Advocacy Award in 2021 and 2023. She also received the Exemplary Teacher Award from the national organization, Real World Ophthalmology. Dr. Haqqie has been recognized as a gifted educator and has astrong interest in teaching the next generation of ophthalmologists.Dr. Haqqie is author and co-author of numerous journal articles and national presentations. Her areas of clinical and research interest include ocularsurface disease, cataract surgery, and ocular emergencies.Dr. Haqqie is a diplomat of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology, American Society of Cataract & Refractive Surgeons, and is an active member of various professional societies. She is committed to excellence in the provision of a complete range of ophthalmic service. Her practice interests include comprehensive ophthalmology, advanced corneal, cataract, and laser vision correction. Dr. Haqqie is currently accepting new patients; appointments can be made by calling 646-962-2020.

Biography: Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr's efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy's Oncology and Pathology's One network.

Care Philosophy: It is a privilege to care for New Yorkers, and patients from around the world, at Weill Cornell. As your doctor, I promise to listen, communicate, and provide exceptional, personalized care. I will work with you to create a customized treatment plan combining the most up-to-date, safe, and effective treatment options tailored to meet your individual priorities and goals. If surgery is necessary, I use minimally invasive or endoscopic approaches to reduce, or eliminate, scarring and recovery time.